We began with a vision, and now we’ve grown into an ophthalmic pharmaceutical company focused on discovering, developing and commercializing first-in-class therapies for treating open-angle glaucoma and other diseases of the eye.
Meet the eye care VISIONaerieS™ building the next major ophthalmic pharmaceutical company.MORE
Aug 14, 2018 4:00 PM EDT
REPORTS AND FILINGS
Review the latest annual report, quarterly reports, and other SEC filings.MORE